◎ Sugi Atlas

Atlas / Drug / Aspirin

Aspirin

drug
On this page

Also known as Acetyl salicylateAcetylsalic acidAcetylsalicylic acidAcetylsalicylic acid (who-ip)Acetylsalicylicum acidumAcidum acetylsalicylicumAcidum acetylsalicylicum (who-ip)Alka rapidAnadin all nightAngettes 75Aspirin component of -pcAspirin component of aggrenoxAspirin component of axotalAspirin component of azdoneAspirin component of codoxyAspirin component of darvon compoundAspirin component of duocoverAspirin component of duoplavinAspirin component of equagesic

Summary

Aspirin (CHEMBL25) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC B01AC06) targeting PTGS1, PTGS2, and ASIC3; indicated across 167 conditions including stroke disorder and thrombotic disease; with CIViC clinical evidence for 13 variant-indication associations (e.g. PIK3CA Amplification in head and neck squamous cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: B01AC06 (+4 more)
  • Targets: 3 (PTGS1, PTGS2, ASIC3)
  • Indications: 167 conditions
  • Clinical trials: 912
  • Precision-oncology evidence (CIViC): 13 variant–indication associations
  • Chemistry: 180.16 Da · C9H8O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL25
NameAspirin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID2244
ChEBICHEBI:15365
ATCB01AC06, N02BA01, N02BA51, A01AD05, N02BA71
Molecular formulaC9H8O4
Molecular weight180.16
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N

SMILES: CC(=O)OC1=CC=CC=C1C(=O)O

IUPAC name: 2-acetyloxybenzoic acid

ChEBI definition: A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, platelet aggregation inhibitor, antipyretic, cyclooxygenase 2 inhibitor, cyclooxygenase 1 inhibitor, prostaglandin antagonist, teratogenic agent, anticoagulant, EC 1.1.1.188 (prostaglandin-F synthase) inhibitor, drug allergen, geroprotector.

Other ChEBI roles (chemical / environmental): plant activator.

Also known as: Acetyl salicylate, Acetylsalic acid, Acetylsalicylic acid, Acetylsalicylic acid (who-ip), Acetylsalicylicum acidum, Acidum acetylsalicylicum, Acidum acetylsalicylicum (who-ip), Alka rapid, Anadin all night, Angettes 75, Aspirin, Aspirin component of -pc

Parent form; salt/anhydrous children: CHEMBL1697753, CHEMBL2296002

Patent coverage: 238,647 distinct patent families (694,602 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 692,813 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition3.250%P23219
PTGS2COX-2Inhibition5.620%P35354
ASIC3ASIC340%Q9UHC3

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Lysine-specific demethylase 4E, RecQ-like DNA helicase BLM, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thyrotropin receptor, Estrogen receptor, Integrin alpha-IIb/beta-3, Cyclooxygenase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2.

Bioactivity

ChEMBL activities: 60 potent at pChembl ≥ 5 of 84 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NAPRT9.3Ki0.5nMCHEMBL_ACT_19323246
BLM8.55Potency2.8nMCHEMBL_ACT_4749918
BLM8.55Potency2.8nMCHEMBL_ACT_4933894
TSHR7.3Potency50.1nMCHEMBL_ACT_3920895
TSHR7.3Potency50.1nMCHEMBL_ACT_4618132
P059796.52IC50300nMCHEMBL_ACT_1511300
P059796.52IC50300nMCHEMBL_ACT_16634203
P059796.52IC50300nMCHEMBL_ACT_1885019
P059796.52IC50300nMCHEMBL_ACT_22824328
P059796.52IC50300nMCHEMBL_ACT_2380519
P059796.52IC50300nMCHEMBL_ACT_2641854
P059796.52IC50300nMCHEMBL_ACT_2997803
P059796.52IC50300nMCHEMBL_ACT_3093055
P059796.52IC50300nMCHEMBL_ACT_3372834
P059796.52IC50300nMCHEMBL_ACT_6379886
P059796.52IC50300nMCHEMBL_ACT_8056063
P059796.46IC50350nMCHEMBL_ACT_12635510
P059796.46IC50350nMCHEMBL_ACT_1485808
P059796.46IC50350nMCHEMBL_ACT_1686922
P059796.46IC50350nMCHEMBL_ACT_1983685
P059796.46IC50350nMCHEMBL_ACT_2133399
P059796.46IC50350nMCHEMBL_ACT_2139083
PTGS16.46IC50350nMCHEMBL_ACT_22817210
P059796.46IC50350nMCHEMBL_ACT_2501458
P059796.46IC50350nMCHEMBL_ACT_2523564
P059796.46IC50350nMCHEMBL_ACT_2584816
O626646.46IC50350nMCHEMBL_ACT_2986832
P059796.46IC50350nMCHEMBL_ACT_8047880
P059796.39IC50411nMCHEMBL_ACT_2985498
HMGB16Kd1000nMCHEMBL_ACT_29087331

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, ASIC3.

Top Reactome pathways

12 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Stimuli-sensing channels1ASIC3
Transport of small molecules1ASIC3
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
Ion channel transport1ASIC3

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

167 indications (19 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
stroke disorder4MONDO:0005098EFO:0000712
thrombotic disease4MONDO:0000831HP:0004419
myocardial infarction4MONDO:0005068EFO:0000612
common cold4MONDO:0005709EFO:0007214
coronary artery disorder4MONDO:0005010EFO:0001645
arthritic joint disease4MONDO:0005578EFO:0005856
acute myocardial infarction4MONDO:0004781EFO:0008583
migraine disorder4MONDO:0005277MONDO:0005277
atrial fibrillation3MONDO:0004981EFO:0000275
hypertensive disorder3MONDO:0005044EFO:0000537
peripheral arterial disease3MONDO:0005386EFO:0004265
infertility disorder3MONDO:0005047EFO:0000545
preeclampsia3MONDO:0005081EFO:0000668
squamous cell carcinoma3MONDO:0005096EFO:0000707
cardiovascular disorder3MONDO:0004995EFO:0000319
psychotic disorder3MONDO:0005485EFO:0005407
heart failure3MONDO:0005252EFO:0003144
atherosclerosis3MONDO:0005311EFO:0003914
venous thromboembolism3MONDO:0005399EFO:0004286
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
breast neoplasm3MONDO:0021100EFO:0003869
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
pneumonia3MONDO:0005249EFO:0003106
injury3MONDO:0021178EFO:0000546
chronic kidney disease3MONDO:0005300EFO:0003884
ischemic disease3MONDO:0005053EFO:0000556
acute coronary syndrome3MONDO:0005542EFO:0005672
heart disorder3MONDO:0005267EFO:0003777
diabetes mellitus3MONDO:0005015EFO:0000400
hypertrophic cardiomyopathy3MONDO:0005045EFO:0000538
acquired polycythemia vera3MONDO:0009891EFO:0002429
vascular disorder3MONDO:0005385EFO:0004264
habitual spontaneous abortion3MONDO:0006774EFO:1000954
retinal vein occlusion3MONDO:0006951EFO:1001157
hepatocellular carcinoma3MONDO:0007256EFO:0000182
aortic valve stenosis3MONDO:0042981EFO:0000266
essential thrombocythemia3MONDO:0005029EFO:0000479
ulcerative colitis3MONDO:0005101EFO:0000729
plasma cell myeloma3MONDO:0009693EFO:0001378
brain aneurysm3MONDO:0005291EFO:0003870
osteonecrosis3MONDO:0005380EFO:0004259
schizoaffective disorder3MONDO:0005487EFO:0005411
cerebral atherosclerosis3MONDO:0006694EFO:1000860
retinal artery occlusion3MONDO:0006948EFO:1001154
rheumatic heart disease3MONDO:0006955EFO:1001161
myocardial ischemia3MONDO:0024644EFO:1001375
cerebrovascular disorder3MONDO:0011057EFO:0003763
Kawasaki disease3MONDO:0012727EFO:0004246
acute chest syndrome3MONDO:0005632EFO:0007129
thrombophilia3MONDO:0002305EFO:0009315
gastric ulcer3MONDO:0001126EFO:0009454
macular degeneration3MONDO:0003004EFO:0009606
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
diabetic retinopathy3MONDO:0005266EFO:0003770
blindness (disorder)3MONDO:0001941HP:0000618
gastric neoplasm3MONDO:0021085MONDO:0001056
pharyngitis3MONDO:0002258MONDO:0002258
cerebral infarction3MONDO:0002679MONDO:0002679
peptic ulcer disease3MONDO:0004247MONDO:0004247
colonic neoplasm3MONDO:0005401MONDO:0021063
fetal growth restriction3MONDO:0005030EFO:0000495
transient ischemic attack3MONDO:0005264EFO:0003764
brain infarction3MONDO:0005394EFO:0004277
ST-elevation myocardial infarction3MONDO:0041656EFO:0008585
meningitis3MONDO:0021108MONDO:0021108
influenza3MONDO:0005812EFO:0007328
asthma3MONDO:0004979MONDO:0004979
cataract3MONDO:0005129MONDO:0005129
type 2 diabetes mellitus3MONDO:0005148MONDO:0005148
osteoarthritis3MONDO:0005178MONDO:0005178
multiple sclerosis3MONDO:0005301MONDO:0005301
hip fracture3MONDO:0005327EFO:0003964
bipolar disorder3MONDO:0004985MONDO:0004985
age-related macular degeneration3MONDO:0005150EFO:0001365
colorectal neoplasm3MONDO:0005335MONDO:0005575
duodenal ulcer2MONDO:0005412EFO:0004607
pulmonary arterial hypertension2MONDO:0015924EFO:0001361
acute lung injury2MONDO:0015796EFO:0004610
glioblastoma2MONDO:0018177EFO:0000519
HIV infectious disease2MONDO:0005109EFO:0000764
acute respiratory distress syndrome2MONDO:0006502EFO:1000637
prostate carcinoma2MONDO:0005159EFO:0001663
neoplasm2MONDO:0005070EFO:0000616
Barrett esophagus2MONDO:0013662EFO:0000280
colorectal adenoma2MONDO:0005484EFO:0005406
nicotine dependence2MONDO:0008575EFO:0003768
metabolic syndrome X2MONDO:0011565EFO:0000195
cutaneous melanoma2MONDO:0005012EFO:0000389
periodontitis2MONDO:0005076EFO:0000649
internal carotid artery stenosis2MONDO:0005189EFO:0002615
ovarian neoplasm2MONDO:0021068EFO:0003893
placental insufficiency2MONDO:0005919EFO:0007443
rectal cancer2MONDO:0006519EFO:1000657
prostate adenocarcinoma2MONDO:0005082EFO:0000673
chronic myeloid leukemia2MONDO:0011996EFO:0000339
vitamin D deficiency2MONDO:0100471EFO:0003762
viral pneumonia2MONDO:0006012EFO:0007541
blood coagulation disease2MONDO:0001531EFO:0009314
respiratory failure2MONDO:0021113EFO:0009686
disseminated intravascular coagulation2MONDO:0001243HP:0005521
major depressive disorder2MONDO:0002009MONDO:0002009
ovarian cancer2MONDO:0008170MONDO:0008170
endometrium neoplasm2MONDO:0021251MONDO:0011962
tuberculosis2MONDO:0018076MONDO:0018076
respiratory system disorder2MONDO:0005087EFO:0000684
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
oral cavity neoplasm2MONDO:0021245EFO:0003868
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
thrombotic thrombocytopenic purpura2MONDO:0018896MONDO:0018896
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
depressive disorder2MONDO:0002050MONDO:0002050
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
hypertriglyceridemia1MONDO:0005347EFO:0004211
head and neck cancer1MONDO:0005627EFO:0006859
oral mucosa leukoplakia1MONDO:0004844HP:0002745
ulcer disease1MONDO:0043839MONDO:0043839
herpes simplex infectious disease1MONDO:0004609EFO:1002022
sickle cell disease1MONDO:0011382MONDO:0011382
hairy cell leukemia1MONDO:0018935EFO:1000956
insomnia0MONDO:0013600EFO:0004698
peripheral vascular disease0MONDO:0005294EFO:0003875
bone fracture0MONDO:0005315EFO:0003931
lung adenocarcinoma0MONDO:0005061EFO:0000571
adenomyosis0MONDO:0010888MONDO:0010888
alcoholic liver disease0MONDO:0043693EFO:0008573

42 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 912.

Phase distribution

PhaseTrials
PHASE4277
Not specified183
PHASE3176
PHASE2130
PHASE163
EARLY_PHASE137
PHASE2/PHASE335
PHASE1/PHASE211

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00135226PHASE4ACTIVE_NOT_RECRUITINGASCEND: A Study of Cardiovascular Events iN Diabetes
NCT00725127PHASE4ACTIVE_NOT_RECRUITINGChronotherapy with Low-dose Aspirin for Primary Prevention
NCT03244020PHASE4ENROLLING_BY_INVITATIONLMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
NCT03378934PHASE4RECRUITINGAnti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
NCT03417388PHASE4ACTIVE_NOT_RECRUITINGWomen’s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
NCT04240834PHASE4RECRUITINGTicagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
NCT04479072PHASE4RECRUITINGAspirin and Preeclampsia
NCT04698031PHASE4ACTIVE_NOT_RECRUITINGEfficacy of Clopidogrel on Incidence of Silent Brain Infarction
NCT04850417PHASE4NOT_YET_RECRUITINGRandomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection
NCT05347069PHASE4RECRUITINGEfficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
NCT05418556PHASE4RECRUITINGTailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent
NCT05578456PHASE4NOT_YET_RECRUITINGEffect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity
NCT05638867PHASE4RECRUITINGNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05868525PHASE4RECRUITINGStroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
NCT05910125PHASE4NOT_YET_RECRUITINGAspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
NCT05932472PHASE4RECRUITINGRandomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial
NCT05955365PHASE4RECRUITINGMonotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
NCT05962034PHASE4RECRUITINGThromboxane Function in Women With Endometriosis
NCT06007222PHASE4RECRUITINGNon-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial
NCT06090890PHASE4RECRUITINGAnti-inflammatory Therapy for Recurrent In-stent Restenosis
NCT06100510PHASE4ENROLLING_BY_INVITATIONPFA 100 Evaluation and Reference Interval HOACNY
NCT06281665PHASE4RECRUITINGTreatment With Aspirin After Preeclampsia: TAP Trial
NCT06290765PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
NCT06451198PHASE4RECRUITINGIndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
NCT06468202PHASE4RECRUITINGEffectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT06486792PHASE4NOT_YET_RECRUITINGStroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
NCT06613191PHASE4NOT_YET_RECRUITINGColonoscopy and Antiplatelet Therapy Trial
NCT06650488PHASE4RECRUITINGClopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
NCT06655376PHASE4RECRUITINGAspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
NCT06676280PHASE4RECRUITINGASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography
NCT06710184PHASE4RECRUITINGTreatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction
NCT06723145PHASE4RECRUITINGOptimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation
NCT06738992PHASE4RECRUITINGSafety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair
NCT06757764PHASE4RECRUITINGThe Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
NCT06763744PHASE4NOT_YET_RECRUITINGGenotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
NCT06873321PHASE4RECRUITINGVTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
NCT07153744PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction
NCT07180472PHASE4NOT_YET_RECRUITINGPrevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol
NCT07281547PHASE4NOT_YET_RECRUITINGLow Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain
NCT07361679PHASE4RECRUITINGLDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

Clinical evidence (CIViC)

Variant × indication × effect (13 predictive associations from 13 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PIK3CA AmplificationHead And Neck Squamous Cell CarcinomaSensitivity/ResponseIbuprofen + Aspirin + SulindacCIViC BEID7186
PIK3CA E542KColorectal CancerSensitivity/ResponseAspirinCIViC BEID2033
PIK3CA E545GColorectal CancerSensitivity/ResponseAspirinCIViC BEID2070
PIK3CA E545KColorectal CancerSensitivity/ResponseAspirinCIViC BEID2039
PIK3CA Exon 21 Mutation AND PIK3CA Exon 10 MutationColorectal CancerSensitivity/ResponseAspirinCIViC BEID12601
PIK3CA H1047LColorectal CancerSensitivity/ResponseAspirinCIViC BEID2828
PIK3CA H1047RColorectal CancerSensitivity/ResponseAspirinCIViC BEID2109
PIK3CA MutationColorectal CancerSensitivity/ResponseAspirinCIViC BEID6375
PIK3CA MutationHead And Neck Squamous Cell CarcinomaSensitivity/ResponseAspirin + Sulindac + CelecoxibCIViC BEID7185
PIK3CA Mutation OR PTEN Mutation OR PIK3R1 MutationColorectal CancerSensitivity/ResponseAspirinCIViC BEID12602
PIK3CA WildtypeColorectal CancerSensitivity/ResponseAspirinCIViC BEID2038
PTGS2 OverexpressionColorectal CancerSensitivity/ResponseAspirinCIViC BEID1573
WNT6 OverexpressionColorectal CancerSensitivity/ResponseAspirinCIViC EEID12651

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (2) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

GuidelineSourceGene(s)DosingRecommendation
Annotation of CPIC Guideline for aceclofenac, aspirin, diclofenac, dipCPICCYP2C9
Annotation of CPIC Guideline for aspirin and G6PDCPICG6PD

PharmGKB also curates 79 clinical and 317 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

408 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2
MAVACOXIBChEMBLPhase 2PTGS1, PTGS2
MIROPROFENChEMBLPhase 2PTGS1, PTGS2
NIFLUMIC ACIDChEMBLPhase 2PTGS1, PTGS2
PHENOTHIAZINEChEMBLPhase 2PTGS1, PTGS2
PIRMAGRELChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot